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Objective: The purpose of this study was to examine the effects of simvastatin pretreatment in the setting of acute limb
ischemia–reperfusion injury in an experimental diabetes model that is associated with a high risk for limb loss.
Methods: Adult male Sprague-Dawley rats were randomized into two groups. Diabetes was induced in the first group by
intravenous streptozotocin injection. The second group served as the nondiabetic group. Eight weeks after the
streptozotocin injection, half of the rats in the diabetic and the nondiabetic groups were further randomized to receive
either intraperitoneal simvastatin (1 mg/kg per day) or saline treatment for 6 weeks. Bilateral hind-limb ischemia was
induced for 4 hours by the tourniquet method. After 24 hours of reperfusion, tissue samples were collected from the
gastrocnemius and anterior tibial muscles bilaterally for measurement of muscle edema, percentage of necrosis, and
malondialdehyde (MDA), glutathione, and myeloperoxidase (MPO) levels.
Results: Ischemic injury was more prominent in diabetic animals. The diabetic animals with limb ischemia exhibited a 7%
increase in tissue edema, a 47% increase in muscle necrosis and MPO level, and a 15% reduction in glutathione levels
compared with the nondiabetic animals (P< .05). Simvastatin treatment with 1 mg/kg for 6 weeks reduced the ischemic
injury. Simvastatin pretreatment led to a 71% reduction in muscle necrosis in diabetic animals (P< .001). The protective
effects of simvastatin pretreatment also correlated with a 23% improvement in tissue edema, a 75% reduction in tissue
myeloperoxidase content, and a 71% increase in glutathione levels in diabetic animals (P < .01). Furthermore, skeletal
muscle injury, characterized by tissue edema and leucosequestration, was significantly less severe with simvastatin
pretreatment compared with the nondiabetic animals (P < .01).
Conclusion: Simvastatin pretreatment reduced limb ischemia–reperfusion injury in diabetic and nondiabetic animals. We
conclude that simvastatin pretreatment may be a potential therapeutic intervention for skeletal muscle ischemia–
reperfusion injury in the clinical setting. (J Vasc Surg 2007;45:590-6.)
Clinical Relevance: In this study, we obtained results suggesting that pretreatment with simvastatin for 6 weeks
ameliorated the tourniquet-induced skeletal muscle ischemia–reperfusion injury in diabetic and nondiabetic rats. Our
results hint that pretreatment with 3-hydroxy-3 methyl-glutaryl-coenzyme A reductase inhibitors (statins) may be useful
in preventing and reducing the severity of acute ischemic events. These effects may be most prominent in patients
suffering from circulation challenges such as those seen in diabetic patients. Nevertheless, this issue requires clinical
evidence.Diabetes mellitus (DM) is a major risk factor for
cardiovascular morbidity and mortality.1 Peripheral arte-
rial disease (PAD) is one of the major complications of
DM.2 DM increases the incidence and severity of limb
ischemia approximately twofold to fourfold.3 Diabetic
PAD often affects distal limb vessels, limiting the potential
for collateral vessel development and reducing the options
for revascularization. Critical limb ischemia requiring am-
putation develops more frequently in patients with DM
than it does in others.4 For patients aged 65 to 74 years,
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590DM heightens the risk of amputation more than 20-fold,
putting these patients at great risk for limb loss.4
Mortality risk is also particularly increased in diabetic
patients with PAD.1,2 Patients with PAD have a greatly
elevated risk of myocardial infarction and stroke, and are six
times more likely to die from cardiovascular causes than
those without the disease.5
Treatment strategies for intensive blood-glucose control
substantially decrease the risk of microvascular complications
such as retinopathy and nephropathy, but not macrovascular
disease, including PAD, coronary artery disease, and stroke in
patients with type 2 diabetes.6 None of the individual drugs
had a substantial effect on cardiovascular outcomes.6
Other strategies rather than glucose control are therefore
necessary to reduce the risk of cardiovascular complica-
tions in DM.
The 3-hydroxy-3-methyl-glutaryl CoA reductase in-
hibitors (statins) are found to reduce the incidence of
stroke, myocardial infarction, and mortality from vascular
complications in patients with vascular disease or vascular
risk factors.7-12 Statins have antioxidant, antithrombotic,
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atins also increase nitric oxide production and block the
interaction between leukocytes and the endothelium. Re-
cent clinical7-11,13 and experimental14-18 evidence suggests
that some beneficial effects of statins are independent of
their lipid-lowering properties and are due to their so-called
pleiotropic effects.19 Furthermore, several clinical studies
have shown beneficial effects of statins in chronic limb
ischemia. Statin use improves walking distance in patients
with chronic limb ischemia20 and is also associated with
improved graft patency and limb salvage after infrainguinal
bypass grafting.21,22 Little is known about the effects of
statins on acute limb ischemia, however.
We hypothesized that statins could also reduce periph-
eral ischemia–reperfusion injury because of their pleiotro-
pic effects. To test this hypothesis, we investigated the
effects of simvastatin pretreatment on the severity of acute
limb ischemia–reperfusion injury in an experimental diabe-
tes model that is associated with a high risk for limb loss.
MATERIALS AND METHODS
Male Sprague-Dawley rats weighing 200 to 250 grams
were housed under diurnal lighting conditions (12 hours of
darkness and 12 hours of light). Before the experiment,
they were made to fast overnight but were given free access
to water. Animal housing, care, and application of experi-
mental procedures were all done in accordance with the
Guidelines for Care and Use of Laboratory Animals, pub-
lished by the National Society for Medical Research and the
National Institutes of Health. All of the animal experiments
described were approved by the Ethics Committee of the
Faculty of Medicine, Ankara University.
Experimental diabetes model. Rats were randomly
divided into two groups. Diabetes was induced in the first
group by 45-mg/kg streptozotocin (STZ) (streptozocin
Zanosar, Pharmacia & Upjohn, Kalamazoo, Mich) in 0.9%
physiologic serum, administered intravenously through the
tail vein under ether anesthesia. Three days after the STZ
injection, blood glucose levels were measured, and the
animals with glucose levels 300 mg/dL were enrolled as
diabetics. Only rats with blood glucose levels300 mg/dL
were entered into the experimental protocols. Animals
receiving STZ without glucose levels 300 were excluded
from the study. The second group served as the nondiabetic
group and received saline alone.
Simvastatin pretreatment. Eight weeks after the STZ
injection, both diabetic and nondiabetic groups were ran-
domly divided into two subgroups and either 1 mg/kg per
day of simvastatin (Merck & Co, Inc, Rahway, NJ) or an
equivalent volume of saline was administered intraperito-
neally for 6 weeks.23 For the preparation of simvastatin, 4.0
mg was dissolved in 0.1 mL 95% ethanol and 0.15 mL 0.1
N sodium hydroxide was added and heated for 2 hours at
500°C. This was neutralized with hydrogen chloride, and
when a pH of 7.2 was reached, distilled water was added,
after which the total dilution volume was 1 mL. The 4.0
mg/mL stock solution was preserved at –20°C for further
use. A total of 36 rats were studied in four groups: (1) 10nondiabetic, (2) 7 nondiabetic pretreated with statin, (3)
10 diabetic, and (4) 9 diabetic pretreated with statin.
Hind-limb ischemia model. All the rats in each
group underwent 4 hours of lower extremity ischemia and
24 hours of reperfusion. Rats were anesthetized with ket-
amine (50 mg/kg, intraperitoneally) (Ketalar, Parke-Davis,
Morris Plains, NJ) and xylazine (10 mg/kg, intraperitone-
ally) (Rompun, Bayer, Leverkusen, Germany). Occlusion
of the lower extremity was performed by the tourniquet
method, as described previously.24 The tourniquet (rub-
ber band, No. 15, MAS, Istanbul, Turkey) was looped
six times briefly as proximally as possible on the thigh.
After 4 hours of ischemia, reperfusion was initiated by
releasing the tourniquet. The rats were hydrated by an
intraperitoneal injection of 40-mg/kg normal saline ev-
ery 2 hours for 8 hours and allowed free access to water.
Biochemical analysis and tissue sampling. After 24
hours of reperfusion, all rats were anesthetized with ket-
amine (200 mg/kg, intraperitoneally), and after laparot-
omy, 5-mL blood samples were obtained from the inferior
vena cava and preserved at –20°C for further use. Plasma
glucose concentrations, glycosylated hemoglobin (HbA1c)
levels, and serum levels of cholesterol, triglyceride, lipopro-
teins (very-low-density lipoprotein [VLDL], high density
lipoprotein [HDL]), and creatinine phosphokinase were
analyzed for possible effects of simvastatin therapy
and DM.
Tissue samples were obtained from the right gastroc-
nemius (whole muscle) to measure of muscle edema. The
left gastrocnemius was used for measurement of percentage
of necrosis. Bilaterally, whole anterior tibial muscles were
used for measurement of malondialdehyde (MDA), gluta-
thione, and myeloperoxidase (MPO) levels. Samples were
obtained randomly.
Determination of tissue edema. The extent of skeletal
muscle edema was determined by determining the ratio of the
wet to dry tissue weight of the gastrocnemius sections.25 The
muscle samples were weighed immediately for measurement
of the wet weight and then freeze-dried for 48 hours with a
freeze-dry system (Heto Drywinner, Thermo Life Sciences,
Basingstoke, UK) for measurement of the dry weight. The
tissue water content was expressed as water content (%) 
[(wet weight – dry weight)/wet weight]  100.
Determination of muscle necrosis. Muscle necrosis
was measured with nitroblue tetrazolium dye to stain the
viable muscle.26 The harvested muscles were immediately
divided into three equal slices and weighed on a scale. The
slices were incubated in 0.05% nitroblue tetrazolium solu-
tion for 20 minutes in a dark room. Viable muscle stained
deep blue, whereas nonviable muscle remained pale and
unstained (Fig 1).
The outline of the muscle slices and the areas of necro-
sis were outlined on a transparency. The total surface area
and the area of necrosis were calculated for each slice by the
use of computerized planimetry. The amount of muscle
necrosis for each slice was measured by the ratio of area
of necrosis/total surface area of the slice multiplied by
the weight of the slice. The total sum of the necrotic
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of necrosis in each muscle and was expressed as a per-
centage. Percentage of necrosis  (total unstained area/
total area)  100.
Measurement of malondialdehyde. MDA is the end
product of the major chain reactions leading to oxidation of
polyunsaturated fatty acids, and measurement of MDA
content is the most widely used method for assessing lipid
peroxidation.27 Tissues were homogenized in ice cold
Tris/potassium chloride buffer (50 mmol, pH 7.4) using a
homogenizer. Tissue MDA levels were determined accord-
ing to the Uchiyama and Mihara method.28 Tissue MDA
level was determined by a method based on the reaction
with thiobarbituric acid (TBA) at 90° to 100°C. In the
TBA test reaction, MDA and TBA react together for pro-
duction of a pink pigment with absorption maximum at
532 nm. The results were expressed as nanomoles per gram
of wet muscle tissue weight.
Measurement of myeloperoxidase activity. Neutro-
phil infiltration after reperfusion injury was assessed by the
increase in tissue MPO enzymatic activity.29 Tissue samples
were homogenized in ice-cold potassium phosphate buffer
(50 mmol/L K2HPO4, pH 6.0) containing hexadecyltrim-
ethylammonium bromide (HETAB, 0.5%). The homogenate
was centrifuged at 15,000g for 10 minutes at 4°C, and the
supernatant was discarded. The pellet was then rehomog-
enized with an equivalent volume of 50 mmol/L K2HPO4
containing 0.5% HETAB and 10 mmol/L ethylenediami-
netetraacetic acid (Sigma, St. Louis, Mo). Tissue MPO activ-
ity was assessed by measuring the hydrogen peroxide-
dependent oxidation of o-dianisidine.2HCl. One unit of
enzyme activity is defined as the amount of MPO present
that causes a change in absorbance of 1.0 unit/min at 655
nm and 37°C, and expressed in units per gram of tissue.29
Measurement of glutathione. Glutathione is a key
antioxidant and is used as an indicator of the reduction
capacity of the tissue. Glutathione was determined by the
spectrophotometric method, which was based on the use of
Ellman’s reagent.30,31 Results were expressed in micro-
moles of glutathione per gram tissue.
Statistical analysis. All statistical analyses were per-
Fig 1. The appearance of gastrocnemius muscles stained with
nitroblue tetrazolium dye just before planimetry. A, Viable muscle
stained dark, and (B) nonviable muscle remained pale and
unstained.formed with an IBM-compatible (IBM, New York, NY)personal computer using the SPSS 12.0 software (SPSS Inc,
Chicago, Ill). Data were expressed as median and quartile.
Continuous variables among groups were compared with
the Kruskal-Wallis one-way analysis of variance, and statis-
tically significant data were further analyzed with the
Mann-Whitney U test. A P  .05 was regarded as statisti-
cally significant.
RESULTS
The STZ-injected rats remained diabetic for 8 weeks
before statin treatment. During this period, polydipsia and
polyuria were observed in all diabetic rats. Three rats (1 in
the diabetic and 2 in the statin pretreated diabetic group)
died during the reperfusion phase.
Results of biochemical measurements including blood
glucose and lipids are presented in Table I. There was a
prominent difference between diabetic and nondiabetic
groups in terms of blood glucose and HbA1c levels. How-
ever, statin pretreatment did not cause any changes in
blood glucose and HbA1c levels. HbA1c levels were found
to be significantly higher in the diabetic and statin-
pretreated diabetic groups compared with nondiabetic sta-
tin-treated and untreated groups (P  .001).
No significant difference was observed in the serum
cholesterol and HDL levels among groups. Triglyceride
and VLDL levels were higher in the diabetic group (81
mg/dL [48 to 96] and 18.4 mg/dL [10.2 to 23.3]) than in
the nondiabetic group (34 mg/dL [30 to 48] P  0.001
and 6.8 mg/dL [6.1 to 9.6], P  .001), respectively. In
diabetic groups, statin pretreatment statistically diminished
the creatinine kinase levels, a measure of muscle injury.
Creatinine kinase levels were also found to be significantly
higher in the diabetic group compared with the nondia-
betic group (P  .001).
Tissue edema. The diabetic group developed larger
water content of the tibialis anterior muscles compared
with the nondiabetic group (P  .05). Statin pretreatment
significantly decreased the water content of the tibialis
anterior muscles, both in the nondiabetic (P .01) and the
diabetic groups (P  .01, Fig 2).
Muscle necrosis. Larger muscle necrosis developed in
the diabetic group compared with the nondiabetic group
(P  .05). The extent of muscle necrosis in the statin
pretreated diabetic group was significantly lower than that
of the diabetic group (P .001). Despite the presence of a
similar trend in nondiabetic groups, it did not reach a
statistically significant value (Fig 2, Table II).
Malondialdehyde levels. After lower limb ischemia–
reperfusion, MDA levels, as the index of lipid peroxidation,
were higher in diabetic group compared with the nondia-
betic group, but it did not reach a statistically significant
value. Furthermore, statin pretreatment did not reduce the
MDA levels in either the diabetic or the nondiabetic group
(Fig 3, Table II).
Glutathione levels. After lower limb ischemia–
reperfusion in the diabetic group, the glutathione activity,
an index of antioxidant capacity, was lower than that in the
nondiabetic group (P .05). Six weeks of statin treatment
artile
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levels both in the nondiabetic (P  .01) and the diabetic
groups (P  .01; Fig 3, Table II).
Myeloperoxidase levels. After lower limb ischemia–
Table I. Biochemical indicators of the experimental group
Nondiabetic
Sta
Blood glucose (mg/dL) 107 (104-111)* 9
HbA1c (%) 1.7 (1.6-1.8)* 1
Cholesterol level (mg/dL) 64 (53-72) 5
Triglyceride (mg/dL) 34 (30-48) 2
HDL (mg/dL) 31 (25-39) 3
VLDL level (mg/dL) 6.8 (6.1-9.6) 6
CK level (IU/L) 585 (350-1652) 46
HB, Hemoglobin; HDL, high-density lipoprotein; VLDL, very-low-density
Values are median (quartile).
*P  .001 compared with the diabetic groups.
†P  .01 compared with the nondiabetic group.
‡P  .05 compared with the diabetic group.
§P  .05 compared with the nondiabetic group.
¶P  .01 compared with the diabetic group.
Fig 2. Box plots show the extent of skeletal muscle edem
weight of the gastrocnemius sections. Whiskers show qu
Table II. Effects on muscle tissue in the experimental gro
Nondiabetic Statin pretreate
Tissue edema (%) 4.4 (4.3-4.6) 3.4 (3.3-
Muscle necrosis (%) 45 (38-53) 46 (26-4
MDA (nmol/g) 31 (26-33) 33 (28-3
GSH (mM/g) 0.28 (0.25-0.34) 0.40 (0.38
MPO (U/g) 28 (26-34) 14 (14-2
MDA, Malondialdehyde; GSH, glutathione; MPO, myeloperoxidase.
Values are median, (quartile).
*P  .01 compared with the untreated groups.
†P  .05 compared with the nondiabetic group.
‡P  .001 compared with the diabetic group.reperfusion in the diabetic group, MPO activity, used as anindex of leukocyte accumulation, was higher than that in
the nondiabetic group (P  .05). Statin pretreatment re-
duced the MPO activity in the diabetic group compared
with the untreated diabetic group (P  .01). Similarly, in
retreated
abetic Diabetic
Statin pretreated
diabetic
-100)* 386 (280-510) 180 (144-464)
5-1.8)* 2.5 (2.0-2.8) 2.3 (2.0-2.9)
-64) 61 (58-67) 52 (34-58)
-57) 81 (48-96)† 36 (20-54)‡
-32) 36 (29-37) 31 (24-39)
8-10.0) 18.4 (10.2-23.3)† 7.3 (4.0-10.9)‡
0-462) 2476 (1954-3108)§ 772 (419-976)¶
rotein; CK, creatinine phosphokinase.
necrosis determined by the ratio of the wet to dry tissue
ranges. *P  .05, ‡P  .01, and †P  .001.
diabetic Diabetic Statin pretreated diabetic
4.7 (4.6-5.0)† 3.6 (3.2-4.2)*
66 (53-75)† 39 (29-53)‡
34 (32-39) 38 (31-44)
)* 0.24 (0.11-0.26)† 0.41 (0.25-0.69)*
41 (43-50)† 10 (5-19)*s
tin p
nondi
1 (85
.7 (1.
6 (47
2 (19
2 (26
.0 (3.
1 (46
lipopa andups
d non
3.5)*
7)
5)
-0.50
0)*the nondiabetic group, statin pretreatment significantly
groups. Whiskers show quartile ranges. *P .05, ‡P .01.
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nondiabetic group (P  .01; Fig 3, Table II).
DISCUSSION
In this study, we obtained results supportive of the fact
that pretreatment with simvastatin for 6 weeks ameliorated
the tourniquet-induced skeletal muscle ischemia–reperfusion
injury in both diabetic and nondiabetic rats. Statin pretreat-
ment was associated with reduced creatinine kinase levels,
tissue edema, muscle necrosis ratio, and MPO activity, as
well as increased glutathione levels in diabetic rats subjected
to limb ischemia-reperfusion. In nondiabetic rats, statin
pretreatment resulted in reduced creatinine kinase levels,
tissue edema, MPO activity and increased glutathione levels
after limb ischemia–reperfusion. Although many experi-
mental and clinical studies present positive effects of statins
on ischemia–reperfusion injury, to our knowledge, this is
the first study showing the effects of prophylactic use of
statins on acute lower extremity ischemia in an experimen-
tal DM model. Results of this study also suggest that DM
aggravates the ischemic damage caused by skeletal muscle
ischemia–reperfusion injury. In diabetic rats, creatinine ki-
nase levels, tissue edema, muscle necrosis ratio and MPO
activities were all increased, and glutathione levels were
decreased.
Current evidence suggests that statins may attenuate
oxidative stress, inflammation, and platelet aggregation, as
well as coagulation, fibrinolysis, and endothelial functions
and help to prevent thrombosis or restenosis.31 Statins may
affect the intracellular prenylation of proteins, which mod-
ulate the activity of small guanosine triphosphate-binding
proteins. This may be an underlying mechanism for some
pleiotropic effects of statins.32
The protective effects of statins have been suggested in
several experimental ischemia models in different tissues:
● Lefer et al33 showed that simvastatin therapy preserved
cardiac contractile functions and perfusion in a rat
cardiac ischemia–reperfusion model by reducing the
leukocyte-endothelial cell interactions independently
from its lipid-lowering effects.
● Amin-Hanjani et al17 showed that long-term prophy-
lactic treatment with mevastatin upregulated the en-
dothelial nitric oxide synthase and showed neuropro-
tective effects by augmenting the cerebral blood flow,
without altering the serum cholesterol levels.
● Yamada et al34 pointed out that pretreatment with
simvastatin enhanced the blood flow within ischemic
brain tissue after middle cerebral artery occlusion.
● Greisenegger et al35 reported that pretreatment with
statins was associated with decreased clinical severity in
patients with acute ischemic cerebrovascular events,
particularly in patients with diabetes.
● Naidu et al36 showed that pretreatment with simvastatin
was protective against lung reperfusion injury in a rodent
model and suggested that the likely mechanisms of pro-
tection included altered free radical generation throughFig 3. Box plots show the levels of malondialdehyde (MDA), glu-
tathione (GSH), and myeloperoxidase (MPO) in the experimentaleffects on nicotinamide adenine dinucleotide phosphate
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tivity.
● Dillon et al37 recently demonstrated that pretreatment
with simvastatin reduces the tissue oxidative damage
and edema associated with skeletal muscle reperfusion
injury.
In addition to experimental evidence, findings from
prospective and observational clinical studies have demon-
strated that statin treatment significantly improves the clin-
ical outcome after cardiovascular events. Data from the
Scandinavian Simvastatin Survival Study on 4444 patients
with known cardiovascular disease revealed that the use of
simvastatin reduced the episodes of new or worsening
intermittent claudication by 38%.38 Treatment with simva-
statin in hypercholesterolemic patients with PAD resulted
in an increase in pain-free and total walking distances, as
well as improvement in physical abilities.20,39 Simvastatin
has been reported to significantly reduce the incidence of
cardiovascular events.12 The recent Diabetes Control and
Complications Trial demonstrated that almost all diabetic
patients with vascular disease should be taking a statin
agent, given the consensus level 1 evidence guidelines.40
The present study shows that statins ameliorate
tourniquet-induced muscle ischemia–reperfusion injury in
the experimental setting. Our results suggest that pretreat-
ment with statins may be useful in preventing and reducing
the severity of acute vascular ischemic events. These effects
may be most prominent in patients who have circulation
challenges such as those seen in diabetic patients. Never-
theless, this implication requires clinical evidence.
The effects of statin pretreatment cannot be accounted
for by the confounding systemic variables, because there
were no differences between blood glucose, cholesterol
levels, and body weights of animals in the treatment group
compared with those of untreated controls. A potential mech-
anism by which statins may exert their beneficial effects is
through their direct antioxidant and anti-inflammatory prop-
erties.32,33,36 In this study, we investigated the antioxidant
capacity by measuring glutathione levels and observed an
increase in glutathione levels with simvastatin therapy. Al-
though we were unable to show reduced MDA levels with
statin pretreatment, some of the ability of simvastatin ther-
apy to reduce ischemia–reperfusion injury may be related to
its antioxidant effects.
One potential mechanism of action is the ability of
statins regulate endothelial nitric oxide synthase.19 It has
been shown recently that pretreatment with statins inhibits
leukocyte-endothelial interaction and prevents neuronal
death in the rat retina after ischemia-reperfusion injury.41
Statins have also been shown to downregulate the expres-
sion of nuclear factor-B and activator protein-1 at the
transcriptional level, both of which are known to have
central roles in ischemia–reperfusion injury.42 Further
studies are required to elucidate the possible mechanisms
by which statin pretreatment attenuates skeletal muscle
ischemia–reperfusion injury.Pretreatment with simvastatin had several beneficial
effects, including reduced tissue edema, leukosequestra-
tion, and increased antioxidant capacity in the nondiabetic
group. The reduction of muscle necrosis was not statisti-
cally significant, however. The reduction in the extent of
necrosis in the simvastatin-treated diabetic group was one
that restored it to the level of nondiabetic animals. One
possible reason for the lack of improvement in necrosis of
the simvastatin-treated nondiabetic animals might be the
difference in the basal endothelial nitric oxide synthase
(eNOS) levels of diabetic and control animals. Although we
did not measure eNOS levels in our study, studies pub-
lished by Lefer et al43 show that basal eNOS levels of
diabetic hearts are much lower than that of controls, and
simvastatin treatment restores the eNOS production and
attenuates the extent of necrosis after ischemia and reper-
fusion of diabetic hearts in vivo. If simvastatin is indeed
restoring eNOS expression as suggested by Lefer et al, this
could be one way of explaining the mechanism of our
findings.
CONCLUSION
In our experimental setting, diabetes mellitus aggra-
vated the ischemic damage after skeletal muscle ischemia–
reperfusion injury, and a 6-week therapy with simvastatin
reduced the lower limb ischemia–reperfusion injury both in
control and diabetic animals. Statin effects were especially
dramatic and independent from serum cholesterol levels in
diabetic rats. Further clinical trials are necessary to elucidate
the effects of statins in acute lower extremity ischemia–
reperfusion injury.
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